DDMAC to get upgrade in reorg

Share this article:

DDMAC is being upgraded from a division to an office, an FDA official said yesterday.

Rachel Behrman, deputy director of FDA's Office of Medical Policy, announced a restructure of the unit that would consist of an office with two divisions. What's the difference? Basically, it's a step up in the agency's org chart.

“An office may consist of several divisions,” explained an agency spokeswoman. “These divisions report to the office heads.”

Details are still being worked out, but the general idea is that the office would hold a division handling the review of healthcare professional-directed materials and one handling the review of DTC advertising.

The unit would continue to be housed within the Office of Medical Policy and would be named the Office of Prescription Drug Promotion, DDMAC director Tom Abrams told Peter Pitts of Porter Novelli and the Center for Medicine in the Public Interest.

The move reflects an increased emphasis on policing promotion from agency brass as well as the growth of the division in recent years. DDMAC has been adding staff as the agency struggles to keep up with a flood of promotional materials submitted.

In April, the division added a third DTC review group, headed by Sangeeta Vaswani and covering consumer promotions for products in the oncology biologics, pulmonary and allergy, psychiatry and anesthetics, analgesics and rheumatology categories. A fourth DTC review group is planned as well.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...